BLCM Bellicum Pharmaceuticals, Inc.

12.19
-0.29  -2%
Previous Close 12.48
Open 12.56
Price To book 2.88
Market Cap 403.53M
Shares 33,103,000
Volume 326,703
Short Ratio 3.75
Av. Daily Volume 651,630

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 planned 2H 2016
BPX-401
Hematological cancers that express the CD19 antigen
Phase 1/2 update February 22, 2017.
BPX-501 - BP-004
Adjunct T-cell therapy administered after allogeneic HSCT - (hematopoietic stem cell transplantation) - cancer
Phase 2 trial initiation of dosing announced February 21, 2017.
BPX-601
Pancreatic cancer
Phase 1/2 commenced March 2017.
BPX-701
PRAME (preferentially-expressed antigen in melanoma) -expressing melanoma, sarcomas and neuroblastoma cancer

Latest News

  1. Bellicum Announces Clinical Presentations at the 22nd Congress of the European Hematology Association
  2. 3 Growth Stocks You Haven't Thought Of
  3. Houston pharmaceutical company announces C-level changes
  4. Bellicum Pharmaceuticals Announces Management Changes
  5. Bellicum Pharmaceuticals, Inc. – Value Analysis (NASDAQ:BLCM) : May 11, 2017
  6. Bellicum Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : BLCM-US : May 9, 2017
  7. Bellicum Pharmaceuticals Reports First Quarter 2017 Financial Results
  8. Bellicum Pharmaceuticals to Present at the Deutsche Bank 42nd Annual Health Care Conference
  9. Biotech Movers: XBiotech, Atara, Bellicum
  10. Bellicum Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : BLCM-US : April 11, 2017
  11. The First CAR-T Drugs Have Left the Gate
  12. Biotech Movers: Sarepta, Bellicum, Novavax
  13. Bellicum Pharmaceuticals Announces Late-Breaking Presentation of Dual-Switch CAR-T / TCR Technology at AACR
  14. Bellicum Pharmaceuticals Announces Closing of Public Offering
  15. Better Buy: Bellicum Pharmaceuticals, Inc. vs. Kite Pharma
  16. ETFs with exposure to Bellicum Pharmaceuticals, Inc. : March 27, 2017
  17. Bellicum Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : BLCM-US : March 24, 2017
  18. Bellicum Pharmaceuticals Announces Pricing of Public Offering of Common Stock
  19. Bellicum Pharmaceuticals Announces Proposed Public Offering of Common Stock
  20. Bellicum Pharmaceuticals, Inc. :BLCM-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017